Cure My Disease

Don't miss your cure!

 Log in / Sign up

Tiny bacterial particles linked to lung damage in sepsis patients

NCT ID NCT07686887

Not yet recruiting Knowledge-focused Sponsor: Southeast University, China Source: ClinicalTrials.gov ↗

First seen Jul 07, 2026 · Last updated Jul 14, 2026 · Updated 4 times

Summary

This study investigates whether a particularly dangerous strain of Klebsiella pneumoniae bacteria (hvKP) raises the risk of lung injury in adults with sepsis, compared to a more common strain. Researchers will analyze blood samples for tiny bacterial particles and markers of a specific type of cell death called ferroptosis. The goal is to better understand why some sepsis patients develop acute lung injury, which could lead to earlier detection and better care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to
If successful, this could identify early warning signs for lung injury in sepsis patients infected with a dangerous bacteria, potentially guiding future treatments.
What could go wrong
This is an observational study, not a treatment trial. It only looks for links, not causes, and may not lead to any direct medical changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LUNG INJURY(ALI) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute lung injury infectious disease with sepsis Klebsiella infectious disease Klebsiella pneumonia Sepsis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE LUNG INJURY(ALI) HYPERVIRULENT KLEBSIELLA PNEUMONIAE INFECTION KLEBSIELLA PNEUMONIAE INFECTION SEPSIS

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.